Supported in part by grant P30 CA16058, National Cancer Institute, Bethesda, Maryland, U.S.A, The Ohio State University Comprehensive Cancer Center Head and Neck Oncology Group, Columbus, Ohio, U.S.A., and the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, U.S.A. Presented at the 6th international symposium of the American Head and Neck Society, August 7–11, 2004, Washington, DC, U.S.A.
Long-Term Results of a Multimodal Intensification Regimen for Previously Untreated Advanced Resectable Squamous Cell Cancer of the Oral Cavity, Oropharynx, or Hypopharynx†
Version of Record online: 2 JAN 2009
Copyright © 2006 The Triological Society
Volume 116, Issue 4, pages 607–612, April 2006
How to Cite
Ozer, E., Grecula, J. C., Agrawal, A., Rhoades, C. A., Young, D. C. and Schuller, D. E. (2006), Long-Term Results of a Multimodal Intensification Regimen for Previously Untreated Advanced Resectable Squamous Cell Cancer of the Oral Cavity, Oropharynx, or Hypopharynx. The Laryngoscope, 116: 607–612. doi: 10.1097/01.mlg.0000208340.42071.f9
- Issue online: 2 JAN 2009
- Version of Record online: 2 JAN 2009
- Manuscript Accepted: 20 JAN 2006
- Head and neck carcinoma;
Background: Long-term disease control of an intensified treatment regimen for previously untreated stage III and IV resectable oral cavity, oropharyngeal, or hypopharyngeal squamous cell carcinoma was analyzed.
Methods: Forty-three patients with previously untreated, advanced stage, resectable squamous carcinomas of the oral cavity, oropharynx, or hypopharynx were enrolled in a prospective phase II institutional clinical trial at a tertiary care National Cancer Institute-designated comprehensive cancer center. It includes preoperative accelerated hyperfractionated radiotherapy with concurrent cisplatin followed immediately by surgery and intraoperative radiotherapy, and completed with early postoperative weekly paclitaxel, two additional cisplatin cycles, and concurrent once-daily radiotherapy beginning on day 28 after surgery.
Results: Forty-three patients enrolled in the study. Protocol compliance was 53%. The range of time at risk was 10.4 to 56.23 months (median, 45 months). The locoregional (93%) and systemic (91%) disease control rates were excellent. Overall long-term survival was 79%.
Conclusions: An intensive treatment regimen that improves compliance and long-term disease control is clearly feasible for this patient population.